The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Official Title: A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
Study ID: NCT03645928
Brief Summary: A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.
Detailed Description: LN-144 (Lifileucel)/LN-145/LN-145-S1 is an adoptive cell transfer therapy that utilizes an autologous TIL for the treatment of patients with unresectable or metastatic melanoma, advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck, and locally advanced or metastatic non-small cell lung cancer. The adoptive cell transfer therapy used in this study involves patients receiving a nonmyeloablative (NMA) lymphodepletion regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2. Patients in Cohorts 1A, 2A, 3A and 3C will receive TIL plus checkpoint inhibitors. Patients in Cohorts 1B, 1C, and 3B will receive autologous TIL as a single therapy.
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California, San Diego, La Jolla, California, United States
University of Southern California, Los Angeles, California, United States
University of California, Los Angeles, Los Angeles, California, United States
University of Colorado, Denver, Colorado, United States
Yale University, New Haven, Connecticut, United States
Georgetown University Medical Center, Washington, District of Columbia, United States
Mount Sinai Medical Center, Miami Beach, Florida, United States
Orlando Health Cancer Institute, Orlando, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
University of Louisville, Louisville, Kentucky, United States
University of Maryland, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Henry Ford Health System, Detroit, Michigan, United States
MD Anderson at Cooper, Camden, New Jersey, United States
Morristown Medical Center, Morristown, New Jersey, United States
Columbia University, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Cincinnati, Cincinnati, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Avera Cancer Institute, Sioux Falls, South Dakota, United States
Huntsman Cancer Hospital, Salt Lake City, Utah, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Centre Léon Berard, Lyon, , France
Klinikum rechts der Isar der Technischen Universität München, München, Bavaria, Germany
Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany
Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, Schleswig-Holstein, Germany
Laiko General Hospital of Athens, Athens, Attiki, Greece
Attikon University General Hospital, Athens, Attiki, Greece
Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
University Hospital Vall d'Hebron, Barcelona, , Spain
ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, , Spain
Hospital General Universitario Gregorio Marañón, Madrid, , Spain
Hospital Universitario Fundacion Jimenez Diaz, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Universitario HM Sanchinarro, Madrid, , Spain
Hospital Regional Universitario de Malaga - Hospital General, Málaga, , Spain
Universitätsspital Basel, Basel, , Switzerland
Universitaetsspital Bern, Bern, , Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland
Guy's Hospital, London, England, United Kingdom
The Royal Marsden NHS Foundation Trust, London, England, United Kingdom
Bristol Haematology and Oncology Centre, Bristol, , United Kingdom
Name: Iovance Biotherapeutics Medical Monitor
Affiliation: Iovance Biotherapeutics
Role: STUDY_DIRECTOR